Your browser doesn't support javascript.
loading
Skin Staining After Injection of Superparamagnetic Iron Oxide for Sentinel Lymph Node Dissection: A Retrospective Study of Two Protocols for Injection and Long-Term Follow-Up.
Mathey, Marie Pierre; Simonson, Colin; Huber, Daniela.
Afiliación
  • Mathey MP; Department of Gynecology and Obstetrics Valais Hospital, Sion, Switzerland.
  • Simonson C; Department of Gynecology and Obstetrics Valais Hospital, Sion, Switzerland.
  • Huber D; Department of Gynecology and Obstetrics Valais Hospital, Sion, Switzerland.
Eur J Breast Health ; 20(3): 223-227, 2024 07 01.
Article en En | MEDLINE | ID: mdl-39257015
ABSTRACT

OBJECTIVE:

Sentinel lymph node (SLN) dissection is a highly accurate surgical procedure allowing detection of lymph node invasion in patients with clinically negative axilla in early breast cancer. Superparamagnetic iron oxide (SPIO) is a marker used during SLN procedure, allowing the same detection rate as isotopes (Tc-99). A drawback of SPIO is skin staining that can occur around the injection site. The goal of this retrospective study was to assess the frequency of skin staining after oncological breast surgery with SPIO, and the impact of two different injection protocols on the rate of skin staining. MATERIALS AND

METHODS:

Data from breast cancer patients undergoing magnetic tracer SLN detection (SLND) procedure in a single department between 2020 and 2022 was reviewed. Injection protocol P1 consisted of retro-areolar injection of Magtrace 0.8 mL. Injection protocol P2, consisted of retro-tumoral injection with 1 mL. Presence of skin staining was assessed at day 10 after surgery. The evolution and satisfaction of the patients was assessed at six and 12 months.

RESULTS:

In total 175 sentinel lymph node biopsy procedures were performed (P1 141/P2 34), consisting of breast conservative surgery (BCS) (P1 70%/P2 53%) or mastectomy (P1 30%/P2 47%) with SLN. SLN detection rate was 97.7%. Skin staining was reported in 23% and occurred more often after BCS (31.6%) compared to mastectomy (6.8%). When BCS was performed, peritumoral injection was associated with a decreased risk of skin staining compared with retro-areolar injection (22.2% vs. 33.3%, respectively). When present skin staining persisted for 12 months, but most of the patients described only a slight discomfort. The low rate of discoloration after mastectomy, as previously reported, can be explained by the removal of skin and glandular tissue in which the tracer accumulates. Less skin staining in P2 may be because of a shorter interval between injection and surgery and the removal of the excess of SPIO during the lumpectomy.

CONCLUSION:

SPIO injection is a safe surgical technique. After mastectomy, the rate of discoloration was low. Despite the persistent skin discoloration in 58.6% in our study, patient satisfaction was high. Deeper injection, reduced doses, massage of the injection site and peritumoral injection may reduce skin staining.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Breast Health Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Breast Health Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Turquía